Search Results

The CDC’s Advisory Committee on Immunization Practices on Wednesday backed the use of Merck’s Capvaxive and Pfizer’s Prevnar 20 in adults between 50-64 years of age, opening a bigger market for the respective companies.

MorphoSys AG announces that Novartis BidCo Germany AG informed the MorphoSys AG Management Board of its intention to merge MorphoSys AG as transferring company into Novartis BidCo Germany AG.

Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease in collaboration with the Biomarkers of Aging Consortium announced the launch of the next phase of the Biomarkers of Aging Challenge Series.

Sirona Biochem Corp. is pleased to announce that its innovative anti-aging ingredient, GlycoProteMim™, has been featured in Stonegate Healthcare’s newly published research report, “Novel Treatments for Age-Related Skin Problems.” The report provides an in-depth analysis of the latest advancements in the $12.5 billion anti-aging skincare market.

RevOpsis Therapeutics and Kemwell Biopharma announced today a broad strategic manufacturing partnership. This collaboration aims to accelerate the development of RevOpsis’ lead candidate, RO-104, a first-in-class tri-specific biologic for the treatment of neovascular age-related macular degeneration (nAMD).

With the FDA’s approval, Fasenra will compete with GSK’s Nucala, which in December 2017 became the first biologic approved for eosinophilic granulomatosis with polyangiitis.